Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 29 January
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer 22 January
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform 19 January
